Sign In

Public policy issues having a direct impact on the discipline are actively monitored and communicated by the Public Policy Committee, which is making recommendations to influence issues as they are raised in the nation's capital.

CDC and the FY 2018

The CDC Coalition urges Congress to Provide $7.8 billion for the Centers for Disease Control and Prevention’s Programs in the FY 2018 [PDF]

Liver Capitol Hill Day 2017

This year’s Liver Capitol Hill Day will bring together AASLD members and their patients with other organizations interested in Liver Disease. Currently there are 105 people who will meet with their legislators on March 29, 2017.

This year AASLD will lobby on behalf of the following issues:

HCV Guidance

HCV Guidance Website Updated to Reflect Latest Drug Developments

More in Public Policy

AASLD Public and Clinical Policy Committee: 2017 Agenda [PDF]



AASLD Position on Treating Patients with Chronic Hepatitis C Virus

AASLD has always put the patient first by providing clinicians with the latest rigorous data on the best treatments for patients with liver diseases, including hepatitis C.

Read AASLD's position.

HCV Guidance FAQ

Chronic hepatitis C virus (HCV) infection affects more than 3 million Americans and is a major cause of liver disease, cirrhosis, and liver cancer. Although several new drugs have now made it possible to cure almost all individuals with this infection, several obstacles remain.

Read the FAQs.